Kornimate/medical-research-clean huggingface dataset:
alleviation of common cold symptoms

Conditions: Common Cold; Pharyngitis; Fever; Congestion; Rhinorrhea; Cough; Sore-throat; Sore Throats Viral; Malaise; Headache; Runny Nose; Sneezing

Summary: upper respiratory infections (uris) have long posed a significant burden to the us healthcare system. well before the coronavirus disease of 2019 (covid-19) pandemic they have been among the most common acute outpatient illnesses, causing 75-100 million physician visits each year on average, and costing the health care system billions of dollars annually. this double-blind randomized placebo-controlled study tested the efficacy of two anti-inflammatory throat sprays against placebo and against a throat spray taken in conjunction with 325mg of aspirin, a well-known systemically administered cyclooxygenase (cox) inhibitor. participants having common cold symptoms lasting less than two days were enrolled and given treatment to administer at home. various common cold symptoms were assessed and measured via clinically validated self-assessment scales. participants were screened for influenza and covid-19 before enrollment and were excluded if found positive.


Eligibility criteria:
inclusion criteria: * otherwise healthy adults with cold symptoms including sore throat who do not meet any of the exclusion criteria listed below, * who rate their sore throat at least a 3 on a 10-point scale, * who have had a sore throat for less than 48 hours by the time they complete the intake clinical trial manager (ctm) assessment. exclusion criteria: * sore throat for more than 2 full days at the time of intake ctm assessment * fever or development of fever during the course of the trial * positive covid-19 test or influenza test at clinical trial administrator (cta) visit * likelihood of strep throat (to be determined by physician pi to the best of their ability) * less than 2 doses of the coronavirus (covid-19) vaccine * any allergies to eggs, milk, or aspirin * females who are pregnant or test positive for pregnancy at the cta visit * any chronic disease such as asthma, hypertension, post-nasal drip, gastroesophageal reflux disease (gerd), cardiopulmonary obstructive disorder (copd), diabetes, cancer, hiv * any history of allergy in the last 14 days for which they took medication * anyone with fever above 101 or who has taken medication other than birth control in the last 30 days * anyone taking an angiotensin converting enzyme (ace) inhibitor * participation in another clinical trial within the last 6 months or during this trial * anyone who smokes

Keywords: common cold pharyngitis fever congestion rhinorrhea cough sore throat malaise headache runny nose sneezing inflammation
an integrated management pathway for complex colorectal polyps

Conditions: Polyp Colorectal

Summary: the purpose of this study is to evaluate the impact of implementing an integrated clinical care pathway for the diagnosis, referral, evaluation and treatment of large complex colorectal polyps on clinical outcomes

our project will create a system that links community hospitals and ambulatory endoscopy centers throughout the province of ontario, directly to the expert endoscopists at our tertiary referral center, to facilitate the timely assessment of polyps based on an electronic referral containing endoscopic video recordings or high-resolution images rather than a paper report through a centralized referral pathway. this polyp adjudication will happen in a timely fashion without involving in-person patient consultation, and will streamline the management of these patients to either referral for surgery or booking for endoscopic polyp removal by therapeutic colonoscopy at our center. specific endoscopy time slots will be reserved for these patients to ensure they have efficient access to their treatment. this system represents a new care model for managing patients with concerning pre-cancerous lesions diagnosed in disparate local hospitals through a centralized process of referral, diagnostic evaluation and treatment at an expert tertiary referral centre. the primary aim of our study will be to track the outcomes of the new standard-of-care clinical pathway. clinical objectives of the project include a reduction in wait times for expert assessment after diagnosis of a large or otherwise concerning polyp combined with reduced wait times for therapeutic removal of these polyps, minimizing unnecessary surgery for benign lesions, and facilitating early recommendation for surgery in those patients who truly require surgical resection. additional objectives include the achievement of excellent rates of clinical success, complication rates similar to those reported in the literature, and high levels of satisfaction from referring doctors at participating centers. a final, major goal is to assess whether this pilot program could serve as a model to be expanded to other academic, tertiary referral centers throughout the province of ontario. our primary research question seeks to compare the diagnostic accuracy of expert polyp adjudication between the different modes of referral (video clip, color photograph, faxed images) against the real-time endoscopic diagnosis during therapeutic colonoscopy and the final pathologic result. the secondary research question is to follow the clinical outcomes of all patients who undergo endoscopic mucosal resection (emr) of a large or complex colorectal polyp to evaluate the efficacy and safety of this procedure at our expert tertiary referral center.

Eligibility criteria:
inclusion criteria: * adult patient 18 years or older * large or complex colorectal polyp found during diagnostic colonoscopy exclusion criteria: * severe medical comorbidities that contraindicate safe endoscopy procedures * inability to provide informed consent

Keywords: large colorectal polyp complex colorectal polyp
the effect of endurance training on body composition and insulin sensitivity in prostate cancer patients receiving androgen deprivation therapy

Conditions: Prostate Cancer

Summary: the purpose of the present study is to investigate if endurance training can be used as a therapeutic action against the adverse metabolic disturbances and unfavourable changes in body composition that accompany the androgen deprivation therapy (adt) treatment in prostate cancer patients.


Eligibility criteria:
inclusion criteria: * prostate cancer patients receiving adt for at least 3 months * healthy age and bmi matched controls exclusion criteria: * severe cardiovascular disease * severe arthritis * severe neuropathy * severe hypertension * therapy with antidiabetic agents * vo2max \> 30.

Keywords: prostate cancer adt endurance training
study of doxorubicin and trabectedin in first line treatment on patients with metastatic leiomyosarcoma

Conditions: Uterus Leiomyosarcoma; Soft Tissue Leiomyosarcoma

Summary: uterine leiomyosarcomas and soft tissues are rare tumors with a poor prognosis when metastatic or locally advanced. they have an average chemosensitivity mainly to doxorubicin, ifosfamide, cisplatin, gemcitabine and trabectedin but response rates in combination in first line does not exceed 55% for uterine leiomyosarcomas and 35% for leiomyosarcomas of soft tissue. the trabectedin is a new cancer drug that has obtained marketing authorization after failure of anthracyclines and ifosfamide in the treatment of soft tissue sarcomas (stm) in europe. it has especially shown efficacy in myxoid liposarcomas, leiomyosarcomas and synoviosarcoma. this study aims to evaluate the usefulness of the combination of trabectedin with doxorubicin in first-line treatment of uterine or soft tissue leiomyosarcoma.


Eligibility criteria:
inclusion criteria: * metastatic leiomyosarcoma (uterus or soft tissue) in inoperable relapse with no previous chemotherapy * at least one measurable lesion according to recist criteria before inclusion. at least one of the target is in a none irradiated area * aged \>/= 18 years and physiological age \</= 70 years * ps \</= 2 * normal hematological function (polymorphonuclear neutrophils \>/= 1500/mm3, platelets \>/= 100 000/mm3) * normal kidney function (creatinine \< 1.5xn) * creatinine phosphokinase \</= 2.5xn * normal hepatic function (total bilirubin \</= 1xn; transaminase \</= 2.5xn and alkaline phosphatase \</= 1.5xn) * cardiac function: normal echography and/or isotopic ventriculography (fr\>30%, fevg \> 50%) * patients able to procreate must use a birth control device during treatment and during 3 months after treatment for women; 5 months for men * signed informed consent * patient under affiliated to a system of care exclusion criteria: * any other histological type of uterus sarcoma (carcinosarcoma...) or soft tissue * specific contraindication to the treatment * previous or evolutive mental disease * previous cancer * symptomatic or known brain metastasis * previous radiotherapy ont he only measurable lesion * previous allograft or autograft * known positive serology (hiv, hbc, hbs) * pregnant or breastfeeding women * impossibility to follow the treatment for geographical, social or mental reason * patients under legal protection
benefits of the use of botox in the treatment of empty nose syndrome syndrome

Conditions: Empty Nose Syndrome; Atrophic Rhinitis

Summary: empty nose syndrome patients suffer from disabling physical symptoms and considerable distress. to date there is no definitive cure for these symptoms. established treatment modalities include saline irrigation, surgical implantation of materials or simply use of cotton wads/ silicon cones to simulate the resistive action to airflow of the resected turbinates. this study will research the effectiveness of a new treatment modality in the treatment of empty nose syndrome. this novel treatment method involves the use of botulinum toxin type a (botox).

background: empty nose syndrome (ens) is the term used to describe the condition resulting from over resection of nasal turbinate. symptoms include depression, dysosmia, bleeding, discharge, crusting, dryness, dysosmia, and pain. treatment modalities include adjunctive comfort measures (primarily irrigation), mechanical measures (silicon cones, cotton wads) and surgical treatment (alloderm implants, plastipore cartilage grafts etc.) we will investigate a new method of treatment for ens. this will involve injection of botulinum toxin type a into the dilator nasalis muscle thus collapsing the internal nasal valve to provide added resistance to air flow. objective: to evaluate effectiveness of botulinum toxin type a in improving overall quality of life in ens patients. methods: ens patients in this study will receive botulinum toxin type a along with adjunctive treatment which will include several measures. first of all, patients will be given a nasal rinse bottle and will be instructed to irrigate their noses twice a day as follows: * irrigate the nose 250cc (about 125cc each side) to clear the mucus. * stop and gently clear the nose. * irrigate the nose 250cc (about 125cc each side) once again. * sit quietly for 10 minutes. no blowing. * do not blow the nose for 2 hours. patients will be asked to use sesame oil once a day to prevent drying of the nasal mucosa with further administration as needed. in addition they will advised to make certain lifestyle modifications that will include sleeping with a cool mist humidifier, drinking plenty of fluids and engaging in regular physical activity. before and after treatment data will be obtained in the form of a breathing test and patient questionnaires that will measure changes in physical and mental health.

Eligibility criteria:
inclusion criteria: * any patient aged 18-65 years of age presenting with a known diagnosis of ens who has no known allergies to botox. exclusion criteria: * patients younger than 18 years or older than 65 years of age. * patients with neuromuscular disorders or neuropathic diseases. * patients with infection and or swelling at the site where botox is to be injected. * patients with known hypersensitivity to any ingredient in the drug formulation (botulinum toxin, human albumin) * patients who are or plan to become pregnant within the time period in which the study will be conducted. * patients who are nursing

Keywords: empty nose syndrome over resection of turbinate atrophic rhinitis
effectiveness of once-daily dose regimen of 7-day and 14-day high dose rabeprazole-levofloxacin based quadruple therapy for h. pylori eradication in thai patients with non-ulcer dyspepsia

Conditions: Helicobacter Pylori Infection

Summary: h.pylori is an organism which causes gastric inflammation, peptic ulcer disease (pud), mucosa associated lymphoid tissue (malt) lymphoma and gastric cancer. practical guideline for treatment of patients with dyspepsia and h.pylori eradication recommended the 14-day triple therapy regimen which had curable about 70% by using proton pump inhibitor (ppi) combined with antibiotics including amoxicillin, clarithromycin and metronidazole. up to date, there has been no evidence about the cure rate for h.pylori eradication with once-daily dose regimen of high dose rabeprazole and levofloxacin based therapy. this research is to study the 7-day and 14-day cure rate of h.pylori eradication treatment with once-daily regimen of high dose rabeprazole-levofloxacin based quadruple therapy.


Eligibility criteria:
inclusion criteria: * thai patients with the age between 18 and 70 years * detecting for h.pylori infection with positive urease test and/or pathological findings of h.pylori and/or positive exclusion criteria: 1. any cases with upper gastrointestinal bleeding 2. being treated with medications affecting the research outcome, for example, by using antibiotics including amoxicillin, clarithromycin, metronidazole or fluoroquinolone within 1 month before the enrollment. 3. contraindicated for gastric biopsy such as coagulopathy. 4. any history of drug allergy for levofloxacin, clarithromycin or rabeprazole. 5. receiving proton pump inhibitor within 4 weeks or receiving any antibiotics or bismuth within 2 weeks. 6. being pregnant or raising children with lactation. 7. having history of h.pylori eradication treatment. 8. having severe underlying disease including end-stage renal disease requiring hemodialysis or peritoneal dialysis (gfr \< 15), cirrhosis with child-pugh classification grade c, immunocompromised host with aids, malignancy and/or bed ridden cerebrovascular disease. 9. any cases who receiving anticoagulant. 10. having previous gastric surgery. 11. unwilling to participate into research. 12. having history of taking previous medications which interacted with the research treatment. 13. having underlying heart disease including congenital long qt syndrome.

Keywords: helicobacter pylori infection non-ulcer dyspepsia rabeprazole-levofloxacin
examination of sleep and family functioning in pediatric craniopharyngioma patients

Conditions: Craniopharyngioma

Summary: pediatric craniopharyngioma patients experience significant endocrine and sleep dysregulation difficulties. sleep is a crucial part of children's healthy development, and sleep difficulties are associated with severe functional morbidity. insufficient sleep, excessive daytime sleepiness, and poor sleep quality have all been significantly related to academic, behavioral, and emotional functioning in children and adolescents. ecological momentary assessments (ema) will be used to collect observational data. ema data will be collected twice daily for one week. for the morning ema administration, participants will be asked about their sleep. during the evening administration, participants will be asked about their daytime sleepiness, overall well-being, and family functioning. covariates also administered during the evening administration include medication administration (y/n) and total screen time. at the end of the ema data collection period (on day 7 or 8), participants will be sent a survey asking them to report - anonymously - their overall experience and satisfaction with the ema data collection method.

after recruitment and informed consent/assent is obtained for the current study, participants will be asked to complete a questionnaire battery online (via redcap) assessing sleep habits, daytime sleepiness, family routines, family functioning, and overall quality of life in the past six months. the relationship between subjective sleep ratings obtained from the parent craniopharyngioma study at st. jude (rt2cr) at diagnosis and 3 months later (t1 and t2) and family functioning/routines at the follow-up study (t3) will be assessed. the researchers have permission to use data for all participants who consent to participate in this follow-up ema study. children will be sent electronic surveys two times per day (i.e., morning and evening) for seven days using ilumivu software (https://ilumivu.com/mema-demo). ilumivu is an established ema tool that offers an in-mobile app for participants to respond to questionnaires in real time with limited burden. this application will send notifications to participants to remind them to complete surveys and record response times for each survey.

Eligibility criteria:
inclusion criteria: * craniopharyngioma diagnosis * access to smartphone or a tablet * agreement to download ilumivu application * the ability for the participant to answer questionnaires (i.e., no cognitive or developmental diagnoses that would preclude understanding and completing child self-report questionnaires) * age between 8 and 18 years old at the time of enrollment onto st. jude protocol rt2cr. * participated in sleep study component of rt2cr exclusion criteria: * limited english proficiency as evidenced by an inability to read and respond to ema survey questions * visual or sensorimotor impairment (e.g., loss of sight)

Keywords: ecological momentary assessment sleepiness fatigue endocrinopathy family functioning
sensory function after wound instillation of capsaicin

Conditions: Primary Hyperalgesia

Summary: the use of capsaicin as a potential analgesic drug for postoperative pain relies on the ability of capsaicin to induce membrane lysis of c-nerve fibers. in a previous randomized placebo controled blinded study of this effect we found a significant effect of capsaicin versus placebo. before surgery all patients were examined by quantitative sensory testing to evaluate sensory function. in this study an identical sensory testing will examine if changes to the sensory function in capsaicin treated patients is identical to placebo treated patients.no new intervention will be performed


Eligibility criteria:
inclusion criteria: * primary groin hernia planned to undergo lichtenstein mesh repair * ability to use pain scales * american society of anesthesiologist class i or ii based upon medical history, physical examination, and screening laboratory results * willing to take oral pain medication (acetaminophen, ibuprofen) for the first week * willing to fill out a diary for four weeks following surgery. exclusion criteria: * a previous lower abdominal surgical procedure * bupivacaine, acetaminophen, ibuprofen, or tramadol * a medical condition likely to alter wound healing or pain ratings * systolic blood pressure greater than 150 or diastolic greater than 95 mm hg * contraindication to general anesthesia * bilateral hernia repair * a history of drug or alcohol abuse within the past two years * use of antihypertensive, antidepressant, or psychotropic drug that has not been stable for 3 months * use of an investigational drug within 3 months or scheduled to receive an investigational drug other than algrx 4975 during the study period.

Keywords: primary and/or secondary hyperalgesia hypoesthesia
study of interest of stiripentol and carbamazepine in the treatment of patients with pharmacoresistant focal epilepsies

Conditions: Pharmacoresistant Focal Epilepsies

Summary: this is a monocentric, open-label clinical study, presenting a retrospective part and a prospective part, studying the data of patients with drug-resistant focal epilepsies and treated with the combination of stiripentol (diacomit®) and carbamazepine.


Eligibility criteria:
inclusion criteria: * retrospective part of the research: the medical records of créer patients with the following criteria will be included in the retrospective part of the research by an investigator: 1. with pharmacoresistant epilepsy, i.e. a history of failure of two well-conducted and well-tolerated antiepileptic treatment regimens, either as monotherapy or as combination therapy, 2. receiving or having received a treatment combining stiripentol and carbamazepine for a period of at least 15 days, 3. having at least one evaluation data after the initiation of treatment with stiripentol and carbamazepine (a follow-up visit after the initiation of the study treatment), 4. for which an information note indicating the possibility of opposing the processing of data has been provided. * prospective part of the research: among the patients whose medical records are included in the retrospective part of the research, those who meet the following criteria will be able to participate in the prospective part of the research: 1. currently treated with stiripentol in combination with carbamazepine for at least 15 days and still being followed in the center, 2. weighing at least 5 kg (minimum weight in accordance with the blood volume taken), 3. having read, or whose parents have read, the information note and signed the consent form. for children, if their level of understanding allows it, their consent will also be sought, 4. having sufficient knowledge, or whose parents or legal guardians have sufficient knowledge, of the french language to read, understand and complete the research documents, 5. members or beneficiaries of a social security scheme. these patients, both children and adults, will be welcomed at the cic. exclusion criteria: - retrospective part of the research : patients objecting to the collection of their data will not participate in the research. - prospective part of the research : patients with the following criteria will not be able to participate in the prospective part of the research: 1. participating simultaneously in another interventional clinical trial or in a period of exclusion following a previous trial, 2. whose state of health does not allow him to give his consent, 3. under guardianship or curatorship, 4. under judicial protection or person deprived of liberty.